Dapagliflozin Vascular Health Trial for Type 2 Diabetes Terminated Early

Trial results for the study "Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes" (NCT05139914) were posted on ClinicalTrials.gov on 2026-02-11. The Phase 4 trial, investigating dapagliflozin for its impact on vascular health in patients with Type 2 Diabetes Mellitus, was terminated early after enrolling only 4 participants.

Background

Patients with Type 2 Diabetes Mellitus (T2DM) often experience changes in blood vessel health, which can increase their risk of cardiovascular events such as heart attacks or strokes. Dapagliflozin is a Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor, a class of medications for T2DM that may offer protective benefits for the heart and blood vessels. The overarching objective of this mechanistic study was to investigate how dapagliflozin impacts vascular health in patients with T2DM.

Trial design

The study, identified as NCT05139914, was a Phase 4 trial with an overall status of TERMINATED. It aimed to assess dapagliflozin as an intervention for patients diagnosed with Diabetes Mellitus, Type 2 and Endothelial Dysfunction. The trial had an enrollment of 4 participants. The study's primary outcomes were not listed in the posted results.

What this means

The early termination of this trial, combined with its very low enrollment of only 4 participants, means that no meaningful conclusions can be drawn regarding dapagliflozin's impact on vascular health in patients with Type 2 Diabetes Mellitus from this specific study. The trial's original objective, to understand the mechanistic effects of an SGLT2 inhibitor on vascular health, remains unaddressed by these results due to the premature cessation of the study. Consequently, this termination prevents any assessment of the drug's potential benefits or risks in this context based solely on the data from NCT05139914.

Source

The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT05139914, titled "Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes," were posted on 2026-02-11 on clinicaltrials.gov.